Nizatidine
 |
|
| Clinical data | |
|---|---|
| Trade names | Axid |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a694030 |
| License data |
|
| Pregnancy category |
|
| Routes of administration |
Oral |
| ATC code | A02BA04 (WHO) |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | >70% |
| Protein binding | 35% |
| Metabolism | Hepatic |
| Biological half-life | 1–2 hours |
| Excretion | Renal |
| Identifiers | |
|
|
| CAS Number | 76963-41-2  |
| PubChem (CID) | 3033637 |
| IUPHAR/BPS | 7248 |
| DrugBank | DB00585 |
| ChemSpider | 2298266 |
| UNII | P41PML4GHR |
| KEGG | D00440 |
| ChEBI | CHEBI:7601  |
| ChEMBL | CHEMBL653 |
| ECHA InfoCard | 100.155.683 |
| Chemical and physical data | |
| Formula | C12H21N5O2S2 |
| Molar mass | 331.46 g/mol |
| 3D model (Jmol) | Interactive image |
|
|
|
|
| (what is this?) (verify) |
|
Nizatidine is a histamine H2 receptor antagonist that inhibits stomach acid production, and is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease. It was developed by Eli Lilly and is marketed under the brand names Tazac and Axid.
Contents
Clinical use[edit]
Nizatidine is used to treat duodenal ulcers, gastric ulcers, and gastroesophageal reflux disease (GERD/GORD), and to prevent stress ulcers.[1]
Adverse effects[edit]
Side effects are uncommon, usually minor, and include diarrhea, constipation, fatigue, drowsiness, headache, and muscle aches.[1]
History and development[edit]
Nizatidine was developed by Eli Lilly, and was first marketed in 1987. It is considered to be equipotent with ranitidine and differs by the substitution of a thiazole ring in place of the furan ring in ranitidine. In September 2000, Eli Lilly announced they would sell the sales and marketing rights for Axid to Reliant Pharmaceuticals.[2] Subsequently, Reliant developed the oral solution of Axid, marketing this in 2004, after gaining approval from the U.S. Food and Drug Administration (FDA).[3] However, a year later, they sold rights of the Axid Oral Solution (including the issued patent[4] protecting the product) to Braintree Laboratories.[5]
Nizatidine proved to be the last new histamine H2 receptor antagonist introduced prior to the advent of proton pump inhibitors.[citation needed]
See also[edit]
- Famotidine (Pepcid) — another popular H2 receptor antagonist
References[edit]
- ^ a b c "Nizatidine". Livertox.nih.gov. Retrieved 2015-10-11.
- ^ [1] Archived May 26, 2008, at the Wayback Machine.
- ^ [2] Archived December 26, 2013, at the Wayback Machine.
- ^ "United States Patent: 6930119". Patft.uspto.gov. Retrieved 2015-10-11.
- ^ [3] Archived August 14, 2007, at the Wayback Machine.
